

## **AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021**

**Ghent, Belgium, June 18<sup>th</sup>, 2021** – [AgomAb Therapeutics NV](#) ('AgomAb'), a biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissue, announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.

“We look forward to showcasing the exciting pharmacology of our HGF/MET agonistic antibody at the EASL conference,” stated **Paolo Michieli, Chief Scientific Officer at AgomAb Therapeutics**. “Being selected for two oral presentations is a testament of our innovative approach of regenerating tissue and restoring organ function by targeting the HGF/MET pathway.”

### **Oral presentation details:**

**Abstract #1: A MET-agonistic antibody mimicking hepatocyte growth factor accelerates liver regeneration and improves survival in mice undergoing carbon tetrachloride exposure and partial hepatectomy**

Presented by Prof Paolo Michieli, PhD on June 25, 2021, at 08.45 CET

Abstract no. OS-687, Abstract session: Liver development and regeneration.

**Abstract #2: A fully agonistic anti-MET antibody protects hepatocytes against acute and chronic injury, promotes fibrosis regression and restores liver function in cirrhotic mice**

Presented by Virginia Morello, PhD on June 25, 2021, at 15.15 CET

Abstract no. OS-874, Abstract session: Targeting liver inflammation and fibrosis.

### **About AgomAb**

AgomAb is pioneering therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery. Our growing pipeline of highly specific monoclonal antibodies is designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes. By combining new scientific insights with robust development expertise, we are building a company to lead to the emergence of truly regenerative medicines.

### **Contacts**

For AgomAb Therapeutics

E-Mail: [info@agomab.com](mailto:info@agomab.com)

### **Media Requests for AgomAb**

Dr. Stephanie May or Dr. Laura Mittmann

Trophic Communications

Phone: +49 171 185 56 82 or + 49 151 5798 4222

E-Mail: [agomab@trophic.eu](mailto:agomab@trophic.eu)